Hi friends, just sharing the following:
https://www.sciencedirect.com/science/article/pii/S0753332220303450
Insight into the molecular evidence supporting the remarkable chemotherapeutic potential of Hibiscus sabdariffa L.
Available online 27 April 2020
Highlights
• Hibiscus sabdariffa (HS) is an ethnomedicinally important herb with a variety of therapeutically important phytochemicals.
• It induces apoptosis by ROS generation that triggers both intrinsic and extrinsic apoptotic cell death
• Inhibition of Matrix metalloproteinases expression plays a vital role in suppression of metastasis and angiogenesis by HS
• With low and selective toxicity, HS-based compounds may be a source of herbal supplement for cancer prevention and treatment
Abstract
Hibiscus sabdariffa or roselle tea is popular around the globe for its antioxidant capability along with various other health benefits.
Besides, it has uses in Ayurvedic and Chinese herbal medicines for the treatment of several diseases.
However, the investigation for the anticancer potential of the plant began roughly in the last decade that emerged with encouraging results.
Both crude extracts and pure compounds of the plant were reported to induce chemoprevention, selective cytotoxicity, cell cycle arrest, apoptosis, autophagy and anti-metastasis effects in varied types of human cancer cells.
The plant contains a high quantity of polyphenolic compounds and at least two of them were proven to induce potent anticancer effects.
Although, the molecular mechanism underlying the anticancer activity was roughly estimated in several studies.
The present review aimed to assemble all ambiguous information to report the molecular evidence establishing the potent anticancer activity of Hibiscus sabdariffa and its implication for cancer therapy.
This study suggests that Hibiscus sabdariffa is an ideal candidate to investigate its role as a herbal supplement for cancer prevention and treatment.
With excellent safety and tolerability record, polyphenolic compounds from the plant need better designed clinical trials.
Thanks.
Kimster
